Agoracom Blog Home

Posts Tagged ‘CBD’

« Older Entries
Newer Entries »

Tetra $TBP.ca Natural Health Adds New Leaders to its Commercial Operations

Posted by AGORACOM-JC at 8:39 AM on Monday, January 14th, 2019

  • Announced that Mr. Derek Theriault has been hired as National Sales Director and Michael Olders has been hired as Director Operations and Logistics.

Derek Theriault, National Sales Director
Michael Olders, Director Operations and Logistics

ORLEANS, Ontario, Jan. 14, 2019 — Tetra Natural Health, a subsidiary of Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Mr. Derek Theriault has been hired as National Sales Director and Michael Olders has been hired as Director Operations and Logistics.

Derek Theriault, National Sales Director – has 20 years’ experience within the pharmaceutical industry and has held various sales and leadership roles during this time. He was pivotal to the launch of several companies including the development of their sales forces and penetration of the Canadian market. Derek has a proven track record for strategically building market-share for several brand name medications, over-the-counter (OTC) drugs and natural products. Derek is recognized for his ability to lead sales teams as well as to help grow the talent base within the organization while reaching and surpassing the milestones that were set forth. He is also known for his passion for coaching, his strong ethical standards and his ability to respond to seize opportunities.

Michael Olders, Director Operations and Logistics – With more than two decades of experience, Michael has held several leadership positions in Operations and Logistics in a variety of industries. Having worked for small privately-owned businesses as well as large multinational corporations, he is known for finding ways to increase efficiencies while lowering costs, often using technology to achieve significant positive results. Teamwork, communication and integrity are hallmarks of Michael’s approach to growing business and profits and exceeding goals. He studied at Selwyn House School, Collège Brébeuf and McGill University, and is passionate about continuous learning, technology, his family and the Montreal Canadiens.

“I am very proud to add Derek Theriault and Michael Olders to the Tetra Natural Health management team. Their combined solid experience and track records with OTC drugs and natural health products will enable us to grow our portfolio of products and our commercial results significantly over the coming year and contribute to the consolidated results of Tetra Bio-Pharma,” says Richard Giguere, Chief Executive Officer of Tetra Natural Health.

About Tetra Natural Health:
Tetra Natural Health inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on identification, development and marketing of hemp or cannabis-based natural health products, or cannabinoids-based products authorized for sale by Health Canada.

About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved and FDA reviewed clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma has subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com

More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

More information at: www.tetrabiopharma.com

For further information, please contact:
Richard Giguère
Chief Executive Officer
Tetra Natural Health
[email protected]

For investors information, please contact:
[email protected]
(438) 504-5784

Media Contact:
Daniel Granger, C.M.
ACJ Communication
T. 514 840-7990
M. 514 232 1556
[email protected]

Charlotte Blanche
T. 514 840-1235 ext. 7772
M. 514 914-0593
[email protected]

Two photos accompanying this announcement are available at: 
http://www.globenewswire.com/NewsRoom/AttachmentNg/7d0b2157-04d4-4cf9-9c4e-1321278ae8d5http://www.globenewswire.com/NewsRoom/AttachmentNg/6d9ea9f6-9ca3-4f8d-b8f1-ffbf17bff3d6

Tags: , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc., Tetra Brio-Pharma Inc. | Comments Off on Tetra $TBP.ca Natural Health Adds New Leaders to its Commercial Operations

CLIENT FEATURE: Applied BioSciences Stands to Deliver Aquiring Majority Stake in Trace Analytics $HTIM $WMD.ca

Posted by AGORACOM at 11:40 AM on Friday, January 11th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png
  • Acquired a majority stake in Trace Analytics, Inc., a leading testing and analytics company.
  • The team has over 65 years of experience in the testing and analytics space and a full-time staff of nine employees including, two Ph.D. analytical chemists and five other scientists. 
  • A recent report from Coherent Market Insights1 estimates that the global cannabis testing market is projected to grow 13.2% year-over-year through 2026, when it is expected to surpass $1.5 billion USD.
  • Applied BioSciences products use base ingredients that are USDA Organic and non-GMO. Offering Vegan, sugar-free, 99% Pure CBD Isolate infused. The products are formulated with CBD extracted from pesticide-free, organically grown, domestically produced, High-CBD Industrial Hemp. Lab-tested and guaranteed Pesticide and Chemical-free.  Our proprietary blends also contain USDA certified organic botanicals, herbals and essential oils to provide synergy with other healing elements found in nature.
  • On December 20, 2018, President Trump signed the US Farm Bill into law. The new law defines hemp as an agricultural product for the first time in 50 years and allows American farmers to plant and harvest hemp. This will allow farmers and researchers of hemp to receive the same benefits as farmers and researchers of other crops, including the ability to apply for insurance and federal grants
  • Applied BioSciences early stage investment in Hightimes Magazine is valued at approximately $1.75 Million at assumed IPO Pricing of $11.00

Link to AppliedSciences Hub

FULL DISCLOSURE: Applied BioSciences is an advertising client of AGORA Internet Relations Corp.

Tags: , , , , ,
Posted in All Recent Posts, Applied BioSciences | Comments Off on CLIENT FEATURE: Applied BioSciences Stands to Deliver Aquiring Majority Stake in Trace Analytics $HTIM $WMD.ca

North Bud Farms Inc. $NBUD.ca – More big consumer companies will bet on pot this year $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 3:11 PM on Thursday, January 10th, 2019

SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Click Here For More Information

  • Marijuana is going mainstream and Wall Street has started to notice. Recreational marijuana is now legal in Canada.
  • And even though there is still a federal ban on pot in the United States, Washington has started to loosen some regulations on other products derived from cannabis, including hemp, following the recent passage of the Farm Bill.

By Paul R. La Monica, CNN Business

New York (CNN Business)Marijuana is going mainstream and Wall Street has started to notice. Recreational marijuana is now legal in Canada. And even though there is still a federal ban on pot in the United States, Washington has started to loosen some regulations on other products derived from cannabis, including hemp, following the recent passage of the Farm Bill.

Several states have also legalized recreational and medical marijuana. That’s why Vivien Azer of Cowen & Co. is extremely bullish about the prospects for cannabis companies.  

Azer is the first analyst at a major stock research firm to start coverage of cannabis companies. She held a call with reporters on Tuesday to discuss her views on the sector. Azer covers Canada’s Canopy Growth (CGC) and Tilray (TLRY) as well as US-based cannabis packaging maker KushCo (KSHB).   She now thinks the market for cannabis in the United States will reach $80 billion by 2030. That sales potential has already attracted the interest of several alcoholic beverage and tobacco giants seeking growth as booze and cigarette sales slump.  

Marlboro owner Altria invests $1.8 billion in cannabis company Cronos   Beer and wine giant Constellation Brands (STZ), which owns Corona, has made a $4 billion investment in Canopy Growth. Budwesier brewer Anheuser-Busch InBev (BUD) has a deal to work with Tilray in Canada. And Marlboro maker Altira (MO) recently bought a 45% stake in Canada’s Cronos (CRON).  

Azer expects more deals like this, particularly from the beverage makers. The rationale: Drink companies view cannabis as a product that could lessen demand for beer, wine and hard alcohol, particularly as more US states legalize marijuana.   “Consumers say they cut back on alcohol when they mix alcohol and cannabis,” Azer said during the conference call Tuesday, adding that she would not be surprised to see Diageo (DEO), the maker of Johnnie Walker, Ketel One and Guinness, to eventually make a deal to get into the cannabis market along with other spirits companies.  

Although Azer is predicting strong demand for legal cannabis in Canada, the United States and other parts of the world, she still thinks that many of the pot stocks got ahead of themselves leading up to the legalization of marijuana in Canada in October — and that is why many of them have fallen in the past few months.  

She added that some dispensaries in Canada were faced with shortages of marijuana and also couldn’t handle demand for online orders. Some were forced to delay shipments. That’s led to some choppy sales in the first few weeks since legalization.   “It comes down to fundamentals. So is it surprising to see the cannabis stocks sell off after Canada’s legalization? No. The runup was too far too fast and there were some companies that reported revenue misses,” Azer said.  

A worker collects cuttings from a marijuana plant at the Canopy Growth Corporation facility in Smiths Falls, Ontario.   Azer concedes that the stocks may remain volatile for a bit because they have attracted so much interest from more fickle individual investors, as opposed to big institutions like mutual funds and hedge funds.  

But she argues that the stocks will stabilize once more long-term investors join some of the short-term traders and start buying them. That might happen sooner rather than later as Wall Street recognizes that marijuana is becoming a legitimate consumer product.  

Piper Jaffray initiated coverage on Canopy and Tilray on Wednesday with outperform ratings. Canadian companies Aurora (ACB) and Aphria (APHA) have recently begun listing in the US, too, which means analysts may begin covering them as well.   Source: https://www.cnn.com/2019/01/09/investing/cannabis-stocks-canopy-tilray-alcohol-tobacco-cowen/index.html

Tags: , , ,
Posted in All Recent Posts, North Bud Farms Inc | Comments Off on North Bud Farms Inc. $NBUD.ca – More big consumer companies will bet on pot this year $ACB $WEED.ca $HIP.ca

Clone Production at Marijuana Company of America’s $MCOA Scio Oregon Hemp Project Underway – Hemp Growers License Renewed for 2019 $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:22 AM on Thursday, January 10th, 2019
  • Clone production for the 2019 season at their Scio, Oregon High Yielding CBD Hemp project is now in high gear, in preparation for an “as early as possible” planting this year
  • Unlike 2018, which had a late start to planting due to delays in finalizing the acquisition of the project’s 109 acre farm, preparations are underway so that planting of this year’s crop can begin in late May to early June.

ESCONDIDO, Calif., Jan. 10, 2019 – via NetworkWire – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTC: MCOA), an innovative hemp and cannabis corporation, and its Joint Venture partner Global Hemp Group Inc. (CSE: GHG/ OTC: GBHPF/ FRA: GHG) are pleased to announce that clone production for the 2019 season at their Scio, Oregon High Yielding CBD Hemp project is now in high gear, in preparation for an “as early as possible” planting this year. Unlike 2018, which had a late start to planting due to delays in finalizing the acquisition of the project’s 109 acre farm, preparations are underway so that planting of this year’s crop can begin in late May to early June. This will provide an additional 45 to 60 days of growing time compared to last year, allowing time for the hemp plants to get considerably larger, which will generate a greater quantity of biomass.

For 2019, the project will cultivate three hemp strains which will offer high CBD content, substantial biomass yield, and ultra low THC levels, along with superior pest resistance and disease tolerance. These strains also have a shorter flowering period, which will allow for an earlier harvest, before the usual Fall rainy season begins in the region.

The hardiest phenotypes were selected for mother plants that will feed the cloning process, which began back in November 2018 soon after the recent harvest and drying operation was complete. This cloning operation will produce the approximately 40,000+ clones required to plant on the farm’s lower 35 acres.

The Scio team is now upgrading the lighting and electrical in the greenhouses for continued expansion of the cloning operation.  It is expected that the cloning operations will produce an excess of clones beyond what is required for the Scio project, which will allow for the sale to other farms in the area. The team continues to talk with local farmers that are interested in partnering to cultivate hemp for the coming season. On-site clone operations will eliminate the need of capital outlay to purchase clones from other growers as was required in 2018 as the result of the late start, an expense of over US$200,000.

In addition, the project’s operating company, Covered Bridge Acres (CBA), has received its registration to cultivate hemp for 2019 from the Oregon Department of Agriculture. Also, for the 2019 season, CBA is now registered to produce or handle agricultural hemp seed, so that the company can establish a breeding program that will potentially generate additional revenue for the project.

Management is currently searching for an offsite warehouse to store biomass and complete hammer mill processing of the material produced from the 2018 harvest. Once the location has been secured, CBA will complete its Land Use Compatibility Statement (LUCS) and apply for its 2019 Industrial Hemp Handler registration that will enable CBA to further process (extract) its material. Management is in ongoing discussions with several potential off takers and processing partners in an effort to monetize the 2018 biomass and prepare for the upcoming 2019 season which will produce significantly more material.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™â€, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

About Global Hemp Group Inc.
Global Hemp Group Inc. (CSE: GHG) (OTC: GBHPF) (FRANKFURT: GHG), is focused on a multi-phased strategy to build a strong presence in the industrial hemp industry in both Canada and the United States. The Company is headquartered in Vancouver, British Columbia, with hemp cultivation operations in New Brunswick and Oregon. The first phase of this strategy is to develop hemp cultivation with the objective of extracting cannabinoids (CBD, CBG, CBN & CBC) and creating a near term revenue stream that will allow the Company to expand and develop successive phases of the strategy. The second phase of the plan will focus on the development of value-added industrial hemp products utilizing the processing of the whole hemp plant, as envisioned in the Company’s Hemp Agro-Industrial Zone (HAIZ) strategy.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWire/MCOA

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , , ,
Posted in All Recent Posts, Featured, Marijuana Company of America | Comments Off on Clone Production at Marijuana Company of America’s $MCOA Scio Oregon Hemp Project Underway – Hemp Growers License Renewed for 2019 $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

$APPB Applied Biosciences Acquires Majority Stake in Cannabis Testing Firm $BOG.ca $NBUD.ca $MCOA $APPB$AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM at 10:27 AM on Wednesday, January 9th, 2019
  • Acquired a majority stake in Trace Analytics, Inc., a leading testing and analytics company
  • Estimates of the Global cannabis testing market is projected to grow 13.2% year-over-year through 2026
  •  Applied BioSciences continues to be at the forefront of the evolving consumer market, using organically grown plants, without pesticides or herbicides as our main ingredient

(January 9, 2018) Los Angeles, CA – Applied Biosciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced that it has acquired a majority stake in Trace Analytics, Inc., a leading testing and analytics company. The team has over 65 years of experience in the testing and analytics space and a full-time staff of nine employees including, two Ph.D. analytical chemists and five other scientists. 

A recent report from Coherent Market Insights1 estimates that the global cannabis testing market is projected to grow 13.2% year-over-year through 2026, when it is expected to surpass $1.5 billion USD.

Although the health benefits of Cannabis and CBD are becoming well known, one of the challenges is the safety and testing of these products which are ingested, vaped and applied topically.  Many products in the market are cheaply-made, with multiple toxins, chemicals and synthetics.   Some of the products include high levels of THC, harmful substances, illegally processed synthetic cannabinoids, and even some that have no CBD at all. Applied Biosciences intends to position Trace as the leading provider of testing solutions for both compliance requirements and consumer safety.

 â€œApplied BioSciences continues to be at the forefront of the evolving consumer market, using organically grown plants, without pesticides or herbicides as our main ingredient.  As the company, continues to expand our product lines it is important to know that our products have been thoroughly tested by trusted labs in the industry for chemicals, pesticides and any harmful materials.  All our products are tested to ensure high-caliber and quality as well as overall safety.  We will now be able to test our products in an expedited fashion as well as from third-party labs and continue to provide the highest standard of testing results and safety protocols on all our products.” commented Chris Bridges, President of Applied BioSciences Corp.

“Applied BioSciences will allow our company and team to expand. We are excited to embark on this new partnership.  Both organizations have a focus on quality and providing the end user the safest possible products.   The leadership teams of both companies have decided to expand the testing offerings to include advanced pesticide testing by purchasing a gas chromatography tandem mass spectrometer (GC/MS/MS) to complement the liquid chromatography tandem mass spectrometer (LC/MS/MS), as well as purchasing an ion coupled plasma mass spectrometer (ICP/MS) for heavy metals testing. These new platforms, once certified, will allow Trace Analytics to certify Washington State’s medical grade cannabis as well as offering advanced analytical testing to the CBD producers / processors from around the world.”  commented Jason Zitzer, COO of Trace Analytics Inc.

Applied BioSciences products use base ingredients that are USDA Organic and non-GMO. Offering Vegan, sugar-free, 99% Pure CBD Isolate infused. The products are formulated with CBD extracted from pesticide-free, organically grown, domestically produced, High-CBD Industrial Hemp. Lab-tested and guaranteed Pesticide and Chemical-free.  Our proprietary blends also contain USDA certified organic botanicals, herbals and essential oils to provide synergy with other healing elements found in nature.

1 Coherent Market Insights – https://www.coherentmarketinsights.com/market-insight/cannabis-testing-market-170

About Applied BioSciences Corp.

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

About Trace Analytics Inc.

Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact

Email: [email protected]  or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com / www.traceanalytics.com

Brands:

www.remedishop.com

www.herbalpet.com

www.canagel.com

Follow us:

Facebook @remedicbd & @HerbalPetMeds

Instagram @remedishop & @herbal_pet

Twitter @remedishop & @herbal_pet

Tags: , , ,
Posted in Applied BioSciences | Comments Off on $APPB Applied Biosciences Acquires Majority Stake in Cannabis Testing Firm $BOG.ca $NBUD.ca $MCOA $APPB$AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

INTERVIEW: NORTHBUD $NBUD.ca Discusses Amendment of Licence Application to Add 500K SQ. FT. of Outdoor Cultivation Area

Posted by AGORACOM-JC at 5:04 PM on Monday, January 7th, 2019

Tags: , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, North Bud Farms Inc | Comments Off on INTERVIEW: NORTHBUD $NBUD.ca Discusses Amendment of Licence Application to Add 500K SQ. FT. of Outdoor Cultivation Area

$APPB Applied Biosciences interviewed by Upticknewswire for The First time on the Stock Day Radio podcast and Discuses the Growth of Their CBD Product Lines $HTI

Posted by AGORACOM at 7:06 AM on Monday, November 26th, 2018

LOS ANGELES, CA / ACCESSWIRE / November 26, 2018 / Applied BioSciences Corp. (OTCQB: APPB) is a diversified cannabinoid therapeutics company that specializes in the medical,bioceutical, and pet health industries. The President of Applied BioSciences, Chris Bridges, joined Stock Day’s Everett Jolly for the first time to discuss the Company’s newly expanded product line, as well as their goals for growth going forward.

Jolly began the interview by asking Bridges for a little bit of background information on the Company, as well as himself. Bridges responded, “We’re a diversified company focused primarily on the CBD market. We have several different brands under our umbrella.” Bridges went on to explain that these included consumer-based brands and their product lines, as well as Herbal Pet, which is a pet-focused brand.

Speaking of his own background, Bridges the stated, “Primarily my background is as a tech entrepreneur and in the payment space. I have been building companies since I was in my early 20’s, and came onboard with Applied BioSciences about two years ago and have been really excited about building this company.”

Jolly noted the crowded CBD industry given the recent popularity of these products and then asked, “What makes your CBD products so special?” Bridges expanded on the uniqueness of his product line and explained, “What makes our products special is that they are completely organic and free of poisons and pesticides. We have done a great job at creating the best-in-class CBD products out there.”

Bridges then discussed the estimated growth of the CBD market, noting that by 2022 this industry will be worth around $22 Billion. Bridges added, “What drove us to create these product lines was focusing on specific targets. We’re looking to achieve products that really solve specific problems.”

The interview then turned to the discussion of one of the Company’s brands, Herbal Pet, which has been growing steadily as a pet line under Bridge’s leadership. Jolly inquired, “When is this brand really going to come to fruition and how big is the demand for this segment?”

Bridges responded, “We’re starting to push the direct to consumer sales, as well as wholesale for the products. There’s a massive and explosive growth for pet-oriented products around CBD. We’re really excited about the potential of this one. It’s one of the biggest growing brands under our umbrella.”

Bridges then discussed the Company’s recently closed deal for financing in the amount of $1 Million and explained that they intend to use the funds for the pure growth and expansion of their umbrella brands and their product lines.

The interview closed with Bridges sharing that the team behind Applied BioSciences is truly special and incredibly experienced in the growth of successful companies. Bridges then continued, “We’re building a great platform and expect to be one of the great leaders in this industry.”

To learn more about Applied BioSciences Corp. listen to the full podcast: https://upticknewswire.com/featured-interview-president-chris-bridges-of-applied-biosciences-corp-otcqb-appb/.

About Applied BioSciences Corp.:

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical,bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

Contact:

Email: [email protected] or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line. Official Website: www.appliedbiocorp.com

Tags: , , , ,
Posted in AGORACOM News And Events, All Recent Posts, Applied BioSciences, Featured, Medical Marijuana Stocks, Small and Micro-Cap Space | Comments Off on $APPB Applied Biosciences interviewed by Upticknewswire for The First time on the Stock Day Radio podcast and Discuses the Growth of Their CBD Product Lines $HTI

North Bud Farms $NBUD.ca Provides Corporate Update $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 4:18 PM on Thursday, November 22nd, 2018

Northbud large

  • Construction cannabis production facility in Low, Quebec remains on schedule as per the timeline provided from our builder NGA Construction
  • Erecting of the steel structure began on the 19th of November and is expected to take approximately 30 days to complete
  • Company expects the building to be operational in Q1 2019

TORONTO, Nov. 22, 2018 — North Bud Farms Inc. (CSE: NBUD) (“NORTHBUD” or the “Company”) is pleased to provide shareholders with an update on our corporate activities.

Construction of our Cannabis Production Facility in Low, Quebec
NORTHBUD is pleased to update shareholders that the construction of our cannabis production facility in Low, Quebec remains on schedule as per the timeline provided from our builder NGA Construction. Erecting of the steel structure began on the 19th of November and is expected to take approximately 30 days to complete. We expect the building to be operational in Q1 2019. Please follow our social media channels for video updates of the facility construction (https://vimeo.com/302330795) and branding out reach.

Cannabis Act Application
Migration of the application to the Cannabis Licensing Tracking System (“CLTS”) has begun in collaboration with Cannabis Consulting Inc., one of the leading consultancy firms in the industry.

Update on Janey’s Inc. Acquisition
NORTHBUD and Janey’s continue to work on finalizing the acquisition agreement to include additional product segments. To date Janey’s has fulfilled multiple orders to the Ontario Cannabis Store and intends to expand its offering in the upcoming product calls.

Corporate Initiatives
NORTHBUD wishes to inform shareholders that its Board of Directors has approved management’s request to explore business opportunities in other international jurisdictions.

“This development represents an evolution in our business since going public and we feel it is important to update shareholders and potential shareholders that we will be actively pursuing international opportunities that we believe are complementary to our core business and that should create value for shareholders as we expand NORTHBUD’s global presence,” said Ryan Brown, CEO of North Bud Farms Inc.

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).   North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.

For more information visit: www.northbud.com.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Tags: , , , , , , ,
Posted in All Recent Posts, Featured, North Bud Farms Inc | Comments Off on North Bud Farms $NBUD.ca Provides Corporate Update $ACB $WEED.ca $HIP.ca

Tetra Bio-Pharma $TBP.ca Enters into Binding Proposal with Quantum Pharma Inc. $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:18 AM on Tuesday, November 20th, 2018

Logo tetrabiopharma rgb web

  • Company takes a significant step forward to become a fully integrated drug development company
  • enables the company to produce cannabis and cannabinoid drug products for Tetra’s and Panag Pharma’s development activities including the ocular drug formulations
  • Quantum Pharma owned by Dr. Peter Ford was the GMP manufacturing division of Ford’s Family Pharmacy and Wellness Centre

ORLEANS, Ontario, Nov. 20, 2018 — Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Quantum Pharma Inc. (“Quantum”) today announced the signing of a binding proposal (the “Proposal“) for exclusive access to a Health Canada licensed facility (i.e., Drug Establishment License; DEL) that enables the company to produce cannabis and cannabinoid drug products for Tetra’s and Panag Pharma’s development activities including the ocular drug formulations.   Quantum Pharma owned by Dr. Peter Ford was the GMP manufacturing division of Ford’s Family Pharmacy and Wellness Centre.  Their formulation expertise will enable Tetra to develop innovative products for future clinical trials. 

The Proposed Transaction is expected to provide Tetra with:

  • Exclusive access to a Health Canada licensed facility (DEL) to fabricate cannabis and cannabinoid drug products for Tetra and Panag’s development activities;
  • Cannabis and cannabinoid drug product formulation expertise; and
  • The ability to manufacture products for all its clinical trials and commercial launches.

Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma stated, “We are very pleased to announce this important development to our shareholders.  We have been working with Ford’s Family Pharmacy and Wellness Centre since 2016.  Dr. Peter Ford and his team have created several innovative formulations and instruments for the fabrication of Tetra’s prescription drugs.  This exclusive agreement not only secures the innovations and production know-how developed for Tetra, but also protects these assets from an acquisition by a competitor.  Quantum Pharma will be an exclusive partner to Tetra and Panag enabling us to execute our future planned trials as well as prepare for our product launches.”

Dr. Chamberland further stated, “Tetra has already entered into various agreements to ensure the supply meets the demand for cannabis, THC and CBD-based products with partners including Aphria Inc., True North Cannabis, a USA-based synthetic cannabinoid manufacturer and a phytocannabinoid supplier.  With the expected completion of the Panag acquisition, Tetra will become vertically integrated with drug development capabilities that range from discovery all the way through to commercial launch.  Our partnerships with Genacol Corporation and Kombucha Baby Brewing Company and its partners provides Tetra with a global sales and distribution platform for the commercialization of OTC drug and wellness products.  In addition, Tetra has also established distribution and sales agreements with two pharmaceutical companies for its PPP001 prescription drug product.”

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Health Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the successful integration of this acquisition,  the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
Media Contact
energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

Tags: , , , , , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Enters into Binding Proposal with Quantum Pharma Inc. $AERO $CBDS $CGRW $APH.ca $GBLX

Revenues at #Cannabis Startups Surge as Demand Begins to Outstrip Supply $BOG.ca $NBUD.ca $MCOA $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 10:51 AM on Wednesday, November 14th, 2018

By Kevin Kelleher

7:30 PM EST

Three of the largest cannabis companies reported earnings this week, painting a portrait of a nascent industry enjoying surging demand as recreational pot becomes legalized in more places—but they’re also encountering some growing pains.

Aurora Cannabis said Monday its revenue rose 260% to $29.7 million Canadian dollars (US$22 million). Net income came in at C$105.5 million, up from C$3.56 million a year ago, largely because of unrealized gains on securities.

On Tuesday, Tilray said revenue rose 86% to C$10 million, while its net loss increased to C$19 million from C$1.8 million a year ago, driven largely by an increase in non-cash stock-based compensation charges.

Also on Tuesday, Cronos Group said revenue in the third quarter rose 186% to C$3.8 million, compared with C$1.3 million a year ago. Cronos lost 4 Canadian cents per share.

Both Tilray and Cronos said that the average price of weed per gram declined. Tilray attributed the decline to an increase in bulk sales as a percentage of total revenue.

However, the price of cannabis could increase in the future because demand is beginning to outstrip supply as Canada and many U.S. states have legalized marijuana. Much of the cannabis sales the three companies reported last quarter came from medicinal marijuana.

“Similar to other Canadian LPs, we are facing demand that outstrips supply,” Aurora’s chief corporate officer Cam Battley said during the company’s earnings conference call. “We anticipate this dynamic to continue for some time.”

Cannabis stocks surged through most of 2018 before encountering a selloff, once pot became legal in Canada, in a classic buy-on-rumor, sell-on-news scenario. Investors appear to be remaining cautious, despite the strong revenue growth last quarter. On Tuesday, Aurora’s stock on the NYSE fell 3.7%, while TIlray fell 1.9% and Cronos fell 1.7%.

Source: http://fortune.com/2018/11/13/revenue-cannabis-startups-surges-demand-outstrip-supply/

Tags: , , , , , , , ,
Posted in All Recent Posts, Bougainville Ventures, Marijuana Company of America, North Bud Farms Inc | Comments Off on Revenues at #Cannabis Startups Surge as Demand Begins to Outstrip Supply $BOG.ca $NBUD.ca $MCOA $ACG.ca $ACB $WEED.ca $HIP.ca

« Older Entries
Newer Entries »